At the time of writing, Xeris Biopharma Holdings Inc [XERS] stock is trading at $7.08, down -2.48%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The XERS shares have lost -4.84% over the last week, with a monthly amount drifted -24.20%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Piper Sandler downgraded its rating to Neutral on November 11, 2024, and kept the price target unchanged to $3. On March 28, 2024, Oppenheimer initiated with an Outperform rating and assigned a price target of $5 on the stock. Craig Hallum started tracking the stock assigning a Buy rating and suggested a price target of $4.50 on August 28, 2023. Jefferies initiated its recommendation with a Buy and recommended $4 as its price target on October 21, 2022. Craig Hallum started tracking with a Buy rating for this stock on April 28, 2022, and assigned it a price target of $6.50. In a note dated November 17, 2021, SVB Leerink initiated an Outperform rating and provided a target price of $6 on this stock.
For the past year, the stock price of Xeris Biopharma Holdings Inc fluctuated between $2.82 and $10.08. Currently, Wall Street analysts expect the stock to reach $18 within the next 12 months. Xeris Biopharma Holdings Inc [NASDAQ: XERS] shares were valued at $7.08 at the most recent close of the market. An investor can expect a potential return of 154.24% based on the average XERS price forecast.
Analyzing the XERS fundamentals
According to Xeris Biopharma Holdings Inc [NASDAQ:XERS], the company’s sales were 266.14M for trailing twelve months, which represents an 37.06% jump. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -0.04%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is 1.14 and Total Capital is -0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -13.32.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.97 points at the first support level, and at 6.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.23, and for the 2nd resistance point, it is at 7.37.
Ratios To Look Out For
It is important to note that Xeris Biopharma Holdings Inc [NASDAQ:XERS] has a current ratio of 1.93. Further, the Quick Ratio stands at 1.35, while the Cash Ratio is 0.62. Considering the valuation of this stock, the price to sales ratio is 4.41.
Transactions by insiders
Recent insider trading involved Shannon John Patrick Jr, that happened on Nov 13 ’25 when 23242.0 shares were sold. Hecht Beth completed a deal on Nov 11 ’25 to sell 16667.0 shares. Meanwhile, Director JOHN SHANNON bought 48149.0 shares on Nov 13 ’25.
